Ketamine hydrochloride is a well known general anesthetic and short acting analgesic in use for almost 3 decades. The role of the NMDA receptor in the processing of nociceptive input has led naturally to renewed clinical interest in N-methyl-d-aspartate (NMDA) receptor antagonists such as ketamine. This paper reviews the use and ef®cacy of low-dose ketamine in the management of acute postoperative pain. The literature was obtained from a computer search of the MEDLINE w database from 1966 through December 1998. Studies were included for review if they were randomized, prospective, controlled, double-blind and reported pain scores. We evaluate the clinical literature and discuss the ef®cacy of low-dose ketamine in the management of acute postoperative pain when administered alone or in conjunction with other agents via the oral, intramuscular, subcutaneous, intravenous and intraspinal routes. Low-dose ketamine is de®ned as a bolus dose of less than 2 mg/g when given intramuscularly or less than 1 mg/kg when administered via the intravenous or epidural route. For continuous i.v. administration low-dose ketamine is de®ned as a rate of #20 mg/kg per min. We conclude that ketamine may provide clinicians with a tool to improve postoperative pain management and to reduce opioid related adverse effects. The evidence suggests that low-dose ketamine may play an important role in postoperative pain management when used as an adjunct to local anesthetics, opioids, or other analgesic agents. Further research is required in the following areas: (a) dose-®nding studies for ketamine as an adjunct to opioids and local anesthetics (b) ef®cacy and optimal route of administration (c) the role of S(1)-ketamine; (d) the in¯uence of ketamine on long-term outcome such as chronic pain (e) long-term physical and chemical stability of mixtures containing ketamine (f) spinal toxicity of ketamine and (g) effects of low-dose ketamine on cognitive and memory functioning after surgery. q 1999 International Association for the Study of Pain. Published by Elsevier Science B.V.
Introduction
A variety of substances and modalities are currently in use for the management of postoperative pain. To optimize pain management and outcome there is a continuous search for new analgesics and alternative routes of delivery. Ketamine is a well known general anesthetic and short acting analgesic in use for almost 3 decades. The recent discovery of the N-methyl-d-aspartate (NMDA) receptor (Foster and Fagg, 1987) and its links to pain processing and spinal neural plasticity triggered renewed interest in ketamine as a potential anti-hyperalgesic agent (Wilcox, 1991) given its actions as a non-competitive NMDA-receptor antagonist.
Ketamine has found a niche as a general anesthetic agent for various procedures in anesthesia and emergency medicine. Its usefulness, however, has been limited by its undesirable psychic emergence effects and cardiovascular stimulating properties. It therefore, remains a controversial drug to many anesthetists who remain wary of its adverse effects. However, it is becoming increasingly clear that a distinction must be made between the use of high-dose ketamine as an anesthetic agent and the use of low-dose ketamine for analgesic or anti-hyperalgesic effects. There may even be a third dose range in which ketamine has no analgesic potency on its own but when used in combination with an opioid, yields an opioid sparing effect and superior pain relief than either drug alone (Chapman and Dickenson, 1992; Dickenson, 1993) . 
